Tokyo, Japan – November 7, 2025 – Neusignal Therapeutics, Inc. (“NTX”) today announced the achievement of first-subject-in (initial subject enrollment and dosing) in a company-sponsored Phase 1 trial of NTX-083, a drug candidate for Alzheimer’s disease.
The trial aims to assess the safety, tolerability, and pharmacokinetics of NTX-083 administered in multiple doses in healthy adults. The results of this clinical trial will inform the Phase Ib trial in patients with Alzheimer’s disease in the United States, which is being prepared in parallel.
The development of NTX-083 is on schedule, and NTX remains fully committed to developing treatments for Alzheimer’s disease.
Information on the trial： https://jrct.mhlw.go.jp/latest-detail/jRCT2071250085
Background
NTX is a Tokyo-based company focused on commercializing early-stage drug discovery from Tohoku University. The development of NTX-083 is supported by the Japan Agency for Medical Research and Development (AMED) under its Strengthening Program for Pharmaceutical Startup Ecosystem (3rd round). NTX provided NTX-083 for the investigator-initiated clinical trial in healthy adults at the University of Tokyo Hospital, where the first-in-human administration of the drug was achieved on February 18, 2025. The trial announced today is the first company-sponsored trial for NTX-083, for which the first subject was dosed with support from Tohoku University Faculty of Pharmaceutical Sciences, the AMED Strengthening Program for Pharmaceutical Startup Ecosystem, investors, and other stakeholders. NTX remains committed to accelerating the development of NTX-083 to address the unmet needs in Alzheimer’s treatment.
This research and development is supported by AMED under project number JP25qfb127005, “Development of KATP channel inhibitor NTX-083 for Alzheimer’s disease therapy.”
Company overview
